Hypothesis\n\nThe X chromosome contributes to cochlear aging resistance through two complementary mechanisms: (1) cellular mosaicism from random X‑inactivation creates subpopulations of spiral ganglion neurons (SGNs) and strial cells that buffer deleterious X‑linked mutations, and (2) a subset of X‑linked genes that escape inactivation provide a dosage‑dependent reserve of stress‑response and neuroprotective proteins that become up‑regulated with age, preserving SGN survival and strial vascular function.\n\n## Mechanistic Rationale\n\n- In female mammals, random XCI yields ~50% of cells expressing the maternal X and 50% the paternal X. If a recessive mutation compromises mitochondrial metabolism or antioxidant defense, only half the cells are affected, allowing metabolic cooperation and reducing the probability of catastrophic SGN loss. This mosaicism mirrors the protective effect seen in the brain where XCI mitigates neurodegeneration.\n\n- Approximately 15‑25% of X‑linked genes escape inactivation, producing higher basal expression in XX cells. Among these are KDM6A, which regulates chromatin accessibility and has been shown to protect neurons from toxin‑induced damage, and genes involved in the NAD+ salvage pathway (e.g., NAMPT) that sustain strial marginal cell ion pumping. Escape genes thus provide a built‑in "genetic backup" that males lack.\n\n- It's known that with advancing age, the inactive X in female cochlear cells undergoes partial reactivation, increasing expression of escape genes. This age‑acquired boost enhances DNA repair capacity and reduces oxidativ

The siege metaphor for autophagy predicts that when nutrients are scarce the cell sacrifices non‑essential components to sustain core functions. In aging kidney, chronic nutrient stress may lock autophagy into a rationing mode that continuously feeds lysosomal catabolism, altering the intracellular amino acid pool that signals to mTORC1 and downstream transcription factors governing p16INK4a expression. We hypothesize that lysosomal efflux of essential amino acids—not autophagic degradation per se—determines whether p16INK4a is induced, such that enhancing efflux can bypass the senescence checkpoint even when autophagic flux is impaired.

Mechanistic rationale

1. Autophagy delivers cytosolic cargo to lysosomes where proteases generate free amino acids.
2. Lysosomal efflux transporters (e.g., SLC38A9, SLC7A5) export these amino acids to the cytosol, reactivating mTORC1 on the lysosomal surface.
3. Active mTORC1 suppresses TF‑EB nuclear translocation and reduces FoxO‑mediated transcription of p21 and p16INK4a.
4. When efflux is blocked, lysosomal amino acid accumulation creates a feedback inhibition of mTORC1 (via Ragulator‑Rag GTPases), sustaining FoxO nuclear activity and driving p16INK4a transcription independent of autophagic flux.

This model reframes autophagy inhibition not as a simple loss of clearance but as a shift in lysosomal nutrient signaling that pushes the cell toward senescence commitment.

Testable predictions

• In murine renal tubular epithelial cells, pharmacological blockade of lysosomal amino acid efflux (using leucine‑analog inhibitor of SLC7A5

Hypothesis

Intermittent administration of a low-dose mTOR inhibitor (e.g., rapamycin) aligned with the late-fasting phase of time-restricted eating (TRE) will potentiate senolytic clearance of senescent cells by boosting TFEB-mediated lysosomal biogenesis, thereby enhancing degradation of senolytic-induced apoptotic debris and extending healthspan beyond that achieved by senolytics + TRE alone.

Mechanistic Rationale

Senolytics such as dasatinib plus quercetin (D+Q) induce apoptosis in senescent cells, generating intracellular debris that must be cleared to prevent secondary inflammation [[https://doi.org/10.1038/s41591-018-0092-9]]. TRE upregulates autophagy markers LC3A, ATG12 and SIRT1, and raises β‑hydroxybutyrate, which further stimulates autophagic flux [[https://pmc.ncbi.nlm.nih.gov/articles/PMC7616065/]]. However, autophagy alone may insufficiently handle the bulk of apoptotic bodies released after senolytic dosing.

Recent work shows that fasting‑activated TFEB translocates to the lysosome, driving expression of lysosomal hydrolases and membrane proteins, thereby expanding degradative capacity [[https://doi.org/10.1016/j.cell.2020.05.018]]. mTORC1 directly phosphorylates TFEB, retaining it in the cytoplasm; thus, transient mTOR inhibition during the fasting window releases TFEB, synergizing with TRE‑induced lysosomal priming.

We propose that a brief rapamycin pulse (e.g., 1 mg/kg oral, 2 h before the end of a 16‑h fast) will:

1. Temporarily inhibit mTORC1, permitting TFEB nuclear translocation.
2. Amplify lysosomal biogenesis and cathepsin activity beyond t

Hypothesis

Reactivate telomerase in differentiated endothelium while simultaneously imposing germline‑style selection against arginase‑driven eNOS uncoupling will synergistically suppress senescence markers and restore a quiescent, anti‑inflammatory phenotype more effectively than either intervention alone.

Rationale

Endothelial cells lose constitutive TERT expression upon differentiation, leading to progressive telomere shortening and replicative senescence [1]. In aging endothelium, elevated arginase‑I/II activity competes with eNOS for L‑arginine, producing superoxide instead of nitric oxide, which drives oxidative DNA damage, telomere attrition, and inflammatory adhesion molecule expression [2]. Telomerase loss sensitizes cells to this oxidative insult, creating a feed‑forward loop where ROS accelerates telomere dysfunction and telomere dysfunction amplifies ROS production [3]. The germline avoids this trap by maintaining high TERT activity and by continuously purging damaged cells through stringent selection at each reproductive bottleneck. Introducing an analogous selection pressure—removing cells that exhibit arginase‑mediated eNOS uncoupling—should reduce the ROS burden that undermines telomerase function, allowing telomere maintenance to exert its full rejuvenative potential.

Novel Mechanistic Insight

Arginase activity consumes L‑arginine and generates urea and ornithine, feeding polyamine synthes

The circadian clock functions as a molecular anti‑aging firewall by sequestering NF‑κB away from inflammatory gene promoters through BMAL1/CLOCK binding at E‑box elements. Age‑related decline of hypothalamic SIRT1 reduces NAD+‑dependent deacetylation of both BMAL1 and the NF‑κB subunit RelA(p65), weakening clock amplitude and increasing NF‑κB transcriptional activity. We hypothesize that selective pharmacological activation of SIRT1 in the mediobasal hypothalamus will re‑establish the competitive advantage of BMAL1/CLOCK over NF‑κB at E‑box sites, thereby suppressing inflammation, restoring GnRH pulsatility, and delaying systemic aging phenotypes.

Mechanistically, SIRT1 deacetylates lysine residues on BMAL1 that enhance its DNA‑binding affinity and promote recruitment of coactivators CBP/p300 to clock‑driven transcription. Simultaneously, SIRT1 deacetylates RelA(p65) at lysine 310, reducing its transcriptional potency and promoting its export from the nucleus. When SIRT1 activity is elevated, the increased affinity of BMAL1/CLOCK for E‑boxes outcompetes RelA for limited coactivator pools, effectively sequestering NF‑κB away from inflammatory promoters. This dual action creates a bistable switch: high SIRT1 → strong clock amplitude → low NF‑κB activity; low SIRT1 → weak clock → high NF‑κB activity.

To test this hypothesis, we will generate a mouse line with inducible, hypothalamus‑specific SIRT1 overexpression (using Sim1‑CreERT2) and treat cohorts with a SIRT1‑activating compound (e.g., SRT2104) versus vehicle. Experimental groups will be aged to 18 months, with longitudi

Background

Myocardial involvement in systemic lupus erythematosus (SLE) remains underdiagnosed, with subclinical myocardial fibrosis contributing to the 2–3 fold excess cardiovascular mortality observed in lupus cohorts. Current cardiac biomarkers (troponin, BNP) detect injury only after substantial myocardial damage has occurred, missing the critical window for cardioprotective intervention.

Soluble ST2 (sST2), the decoy receptor for IL-33, is released by cardiomyocytes and cardiac fibroblasts under mechanical stress and pro-inflammatory signaling. In heart failure populations, sST2 trajectories predict fibrosis progression independent of natriuretic peptides. However, its longitudinal kinetics in autoimmune-mediated myocardial injury remain unexplored.

Hypothesis

Serial serum sST2 measurements obtained every 4 weeks, when modeled as patient-specific linear trajectory slopes and combined with baseline cardiac MRI native T1 mapping values, will predict myocardial fibrosis progression (defined as ≥50 ms increase in native T1 on follow-up CMR) in SLE patients 8–20 weeks before conventional biomarker elevation (troponin I >99th percentile URL or BNP >100 pg/mL), with an area under the ROC curve ≥0.82.

Rationale

The IL-33/ST2 axis operates at the intersection of cardiac mechanotransduction and autoimmune inflammation. In SLE, type I interferon signaling upregulates sST2 expression in cardiac fibroblasts via STAT1-dependent promoter activation, creating a disease-specific amplification loop. Native T1 mapping by CMR detects diffuse myocardial fibrosis at subclinic

Core Hypothesis

Sleep disturbance reduces the amplitude of systemic NAD+ rhythms, uncoupling two NAD+-dependent repair processes: astrocytic glymphatic clearance in the brain and autophagy in Zone 3 hepatocytes. This concurrent failure creates a bidirectional vulnerability where neurodegeneration and non‑alcoholic fatty liver disease (NAFLD) co‑progress, rather than arising independently.

Mechanistic Rationale

1. NAD+ as a circadian messenger – Hepatic autophagy genes (Atg5, Ulk1, Foxo3) show ZT6 peaks that depend on NAD+/SIRT1 signaling [2]. Likewise, astrocytic AQP4 polarization and glymphatic influx peak during sleep and are enhanced by SIRT1‑mediated deacetylation of aquaporin channels (studies show NAD+ boosters increase CSF tracer clearance). Sleep loss blunts NAD+ oscillations, lowering SIRT1 activity in both compartments.
2. Lactate‑mediated coupling – During sleep, astrocytes release lactate that travels via the portal circulation to the liver. Lactate activates hepatic SIRT3, which deacetylates and activates LC3‑II, promoting autophagosome formation. When sleep is fragmented, astrocytic lactate efflux falls, reducing hepatic SIRT3 activity and attenuating Zone 3 autophagy specifically.
3. Senocyte accumulation as a read‑out – Failed autophagy lets damaged mitochondria and lipid aggregates persist, driving senescence preferentially in Zone 3 [4]. Senescent hepatocytes secrete SASP factors (IL‑6, TNF‑α) that cross the blood‑brain barrier, suppressing astrocytic NAD+ synthesis via CD38 upregulation, creating a vicious loop.
4. **Therapeutic p

Hypothesis

Age‑associated NAD+ loss in B cells reduces SIRT1 activity, leading to hypoacetylated chromatin at immunoglobulin switch (S) regions and the Aicda locus. This chromatin state impedes AID access, thereby lowering class‑switch recombination (CSR) and contributing to the observed decline in antibody diversity.

Mechanistic Basis

SIRT1, an NAD+-dependent deacetylase, removes acetyl groups from histone H3K9ac and promotes a permissive euchromatin environment. When NAD+ falls, SIRT1 activity drops, allowing accumulation of repressive marks such as H3K9me3 at S regions and the Aicda promoter. Concurrently, PARP1 hyperactivation—driven by age‑related DNA damage—consumes NAD+ and deposits PAR chains that further compact chromatin. The combined effect creates a "closed" configuration that sterically hinders AID binding and its deaminase activity on switch DNA.

Predictions

1. In aged B cells, ChIP‑seq will show decreased H3K9ac and increased H3K9me3 at Sμ, Sγ1, and the Aicda promoter compared with young cells.
2. Restoring NAD+ (via NMN or CD38 inhibition) will increase SIRT1 activity, elevate H3K9ac, reduce H3K9me3, and rescue AID binding and CSR efficiency in vitro.
3. Genetic ablation of SIRT1 in young B cells will mimic the aged chromatin profile and suppress CSR, even when NAD+ levels are normal.

Experimental Design

• Isolation: Purify naïve splenic B cells from young (3 mo) and aged (20 mo) mice.
• Metabolic modulation: Treat aged cells with NMN (500 µM) or the CD38 inhibitor 78c (10 µM) for 24 h; include vehicle controls.
• Readouts:
  • Me

Background

Age‑related hypercoagulability is marked by a progressive rise in von Willebrand factor (VWF) and Factor VIII (FVIII), driven by endothelial dysfunction, reduced ADAMTS13 activity, and inflammatory amplification [1][2][3]. Pain, particularly chronic nociceptive input, activates sympathetic and stress‑hormone pathways that can transiently increase endothelial shear stress and stimulate ADAMTS13 release, thereby limiting ultra‑large VWF multimer accumulation [4]. Meanwhile, widely used analgesics—NSAIDs, COX‑2 selective inhibitors, and opioids—suppress prostanoid signaling and alter neuro‑immune communication, yet their long‑term impact on the VWF/FVIII axis remains unexplored.

Hypothesis

Long‑term pharmacological suppression of pain (via NSAIDs, COX‑2 inhibitors, or opioids) accelerates the age‑associated increase in plasma VWF antigen and FVIII activity by (i) diminishing endothelial‑derived prostacyclin (PGI2) and nitric oxide (NO) bioavailability, (ii) reducing pain‑evoked sympathetic bursts that normally upregulate ADAMTS13 transcription and secretion, and (iii) shifting the homeostatic set‑point toward a prothrombotic endothelial phenotype. Consequently, habitual analgesic users will exhibit a steeper decade‑wise rise in VWF/FVIII and a faster decline in ADAMTS13 activity compared with matched non‑users, independent of baseline inflammation.

Mechanistic Rationale

1. Prostanoid‑Endothelial Crosstalk – COX‑derived PGI2 and thromboxane A2 (TXA2) balance endothelial vasodilatory and prothrombotic tones. Chronic COX inhibition lowers PGI2, reducing

Hypothesis

Chronic suppression of mTORC1 extends lifespan by shifting cells toward a survival‑oriented state, but longevity benefits depend on preserving mTORC2‑driven actin cytoskeleton remodeling that sustains multicellular coordination. When mTORC2 activity falls below a tissue‑specific threshold, cells gain cell‑autonomous stress resistance yet lose the ability to participate in the organism’s "civilization"—the coordinated behaviors of proliferation, differentiation, and extracellular matrix production that define functional tissues. This uncoupling predicts that interventions inhibiting only mTORC1 will improve healthspan, whereas combined or selective mTORC2 inhibition will accelerate functional decline despite heightened cellular stress defenses.

Mechanistic Rationale

• mTORC1 primarily regulates protein synthesis and autophagy in response to nutrients, acting as the classic growth‑versus‑maintenance switch [1][2].
• mTORC2 phosphorylates Akt and, critically, activates Rho GTPases (Rac1, Cdc42) that drive actin polymerization, focal adhesion formation, and intercellular signaling [5].
• Actin dynamics downstream of mTORC2 determine tissue architecture: stable cortical actin supports epithelial barrier integrity, while dynamic protrusions enable coordinated migration during development and repair.
• In aged or senescent cells, mTORC1 becomes constitutively active and mTORC2 signaling becomes dysregulated, leading to fragmented actin networks and loss of tissue cohesion [3].
• Caloric restriction and rapamycin preferentially dampen mTORC1 while sparing mTORC2 a

Hypothesis: Metabolic Priming via AMPK Activation Creates a Vulnerable Window for Senolytic Action

Core Idea: Senescent cells exhibit fluctuating metabolic states; transient AMPK activation (e.g., through exercise, fasting, or pharmacologic agents like AICAR) lowers intracellular ATP, increases NAD+/NADH ratio, and transiently suppresses BCL-2 family anti-apoptotic proteins, rendering senescent cells more susceptible to senolytic-induced apoptosis. Synchronizing senolytic dosing to these AMPK-high phases should increase clearance efficacy while allowing lower drug exposure, reducing off-target toxicity.

Mechanistic Rationale:

• AMPK activation phosphorylates and inhibits mTORC1, shifting cells toward autophagy and reducing SASP secretion [mTOR inhibition and AMPK activation modulate senescent cell survival and inflammatory SASP]
• AMPK-driven NAD+ biosynthesis via NAMPT elevates SIRT1 activity, which deacetylates p53 and FOXO transcription factors, promoting expression of pro-apoptotic BH3-only proteins (e.g., PUMA, NOXA) [NAD+ restoration reconfigures metabolism and rejuvenates senescent human mesenchymal stem cells]
• Transient AMPK activation also decreases mitochondrial membrane potential, priming the intrinsic apoptosis pathway; senolytics such as dasatinib + quercetin rely on inhibition of SRC family kinases and BCL-XL/Bcl-2 to trigger caspase activation [[Senolytics improve physical function and can increase lifespan by 36% in old mice](https://doi.org/

Hypothesis

Selective autophagy of canonical JAK-STAT proteins enforces a signaling hierarchy that preserves basal ISG expression via STAT2‑IRF9 in aged tissues.

Mechanistic rationale

• In nutrient stress or oxidative stress, autophagy receptors p62/SQSTM1 and NBR1 bind phosphorylated JAK1/JAK2 and pSTAT1 through LIR motifs that become exposed after K63‑linked ubiquitination by TRIM21 (6).
• This ubiquitination is favored on canonical JAKs because their kinase domains acquire activating phosphorylations (Y1007/Y1008) that create a phosphodegron recognized by the E3 ligase, whereas STAT2 and IRF9 lack comparable motifs and remain largely nuclear, shielded from cytosolic autophagy machinery.
• Consequently, autophagic flux preferentially degrades JAK1, JAK2, and pSTAT1, dampening canonical JAK‑STAT signaling while sparing the STAT2‑IRF9 complex that can drive ISG transcription independently of JAK phosphorylation (3).
• The resulting shift maintains a low‑grade interferon tone that supports homeostatic functions but avoids the hyper‑activation that drives senescence in stem/progenitor cells (1).
• When this selective autophagy is impaired—e.g., by mutation of the LIR motif in JAK1 or by pharmacological inhibition of p62 oligomerization—canonical components accumulate, leading to erratic JAK‑STAT activation, loss of the compensatory STAT2

Hypothesis

Low‑dose mitochondrial uncoupling (e.g., 2,4‑dinitrophenol, DNP) administered shortly before dasatinib plus quercetin (D+Q) will sensitize senescent cells to apoptosis by destabilizing anti‑apoptotic Bcl‑2 family proteins, thereby increasing senolytic clearance beyond that achieved by D+Q alone.

Mechanistic Rationale

Recent work shows that mitochondrial stress markedly improves senolytic efficacy by disrupting the anti‑apoptotic shield of senescent cells12. This effect is thought to arise from oxidative activation of pro‑apoptotic BH3‑only proteins (e.g., BIM, PUMA) and concurrent degradation of MCL‑1 via GSK‑3β–dependent phosphorylation3. We propose that a brief, sub‑toxic pulse of DNP will transiently collapse the mitochondrial membrane potential, elevating matrix ROS without triggering necrosis. This ROS burst should:

• Oxidatively inhibit Bcl‑2 and Bcl‑xL cysteine residues, reducing their binding affinity for pro‑apoptotic effectors.
• Activate the AMPK‑GSK‑3β axis, accelerating MCL‑1 turnover.
• Lower the threshold for BAX/BAK oligomerization, priming cells for D+Q‑induced Src‑family kinase inhibition.

Importantly, mitochondrial ROS also modulate the SASP. Elevated ROS can suppress NF‑κB‑driven IL‑6 transcription through oxidation of IKKβ, weakening the IL‑6 autocrine loop that sustains senescence[5](https://www.fightaging.org/archives/2022/04/a

Hypothesis

Aging is an actively maintained, population‑level trait that limits individual lifespan after reproduction to free resources for kin, mediated by a conserved senescence‑associated secretory phenotype (SASP) that signals nutritional status to relatives.

Mechanistic Basis

Recent work shows that extrinsic mortality shapes aging rates, supporting selection gradients rather than programmed traits[3]. Yet the quasi‑program concept highlights that pathways like mTOR remain active post‑maturity, creating a developmental shadow that could be co‑opted for signaling[2]. We propose that, in addition to cell‑autonomous damage, senescent cells release specific SASP factors (e.g., IGF‑BP3, TGF‑β1) packaged in extracellular vesicles that travel through the bloodstream to offspring or close relatives, transiently suppressing mTOR activity in their tissues. This inter‑organismal cue reduces somatic growth and reproductive effort in recipients, thereby conserving nutrients for the senescent individual's kin. The machinery is conserved because the same vesicles also carry microRNAs that modulate epigenetic marks in germ cells, providing a transgenerational inheritance route that reinforces the trait[5].

Predictions and Experiments

1. SASP vesicle transfer – Isolate plasma from old (≥20 mo) mice and young (3 mo) mice, label vesicles with a fluorescent dye, and inject into young recipients. We predict a significant reduction in phospho‑S6K (mTOR readout) in liver and muscle of recipients within 6 h, absent when vesicles are depleted of IGF‑BP3/TGF‑β1 via immunoprecipita

Restoring circadian amplitude in liver, adipose, and skeletal muscle via AAV-delivered BMAL1 and CLOCK re-synchronizes systemic NAD+ cycles, boosting SIRT1 activity and mitigating age-related mitochondrial decline and inflammation.

We hypothesize that a triple‑tissue AAV cocktail—AAV9‑BMAL1 to liver, AAV1‑BMAL1 to skeletal muscle, and AAV6‑BMAL1 to adipose—will reinstate coherent circadian transcription of NAMPT and NAD+‑dependent deacetylases across these metabolic hubs. Elevated NAD+ will activate SIRT1 and SIRT3, enhancing mitochondrial oxidative capacity, reducing ROS production, and suppressing NF‑κB‑driven inflammasome signaling. Consequently, treated aged mice should show improved glucose tolerance, increased endurance, and lower circulating IL‑6 and TNF‑α compared with controls receiving single‑tissue or empty vectors.

To test this, we will inject 20‑month‑old C57BL/6J mice with the triple‑tissue AAV mix or appropriate controls and monitor circadian gene expression (Bmal1, Clock, Per2) in each tissue via qPCR at 4‑hour intervals over 24 h. NAD+ levels will be measured by LC‑MS, SIRT1 activity by fluorometric assay, and mitochondrial respiration in isolated myofibers and hepatocytes using Seahorse. Systemic phenotypes will be assessed by intraperitoneal glucose tolerance test, treadmill exhaustion time, and plasma cytokine multiplex. A successful outcome is defined as ≥20 % increase in NAD+ amplitude, ≥15 % improvement in glucose clearance, and ≥30 % reduction in pro‑inflammatory cytokines relative to baseline aged controls. Failure to observe any of these changes

Hypothesis

Gut‑derived indole‑3‑propionic acid (IPA) activates AMPK in somatic stem cells, triggering a germline‑like quality‑control program that removes damaged components through heightened piRNA‑mediated transposon silencing, selective mitophagy, and asymmetric segregation of cellular debris.

Mechanistic rationale

Recent work shows that the germline sustains its integrity across generations not by passive durability but by relentless culling of defective lineages at each reproductive bottleneck [[https://pmc.ncbi.nlm.nih.gov/articles/PMC9255434/]]. Key effectors include piRNA pathways, mitochondrial quality control via mitophagy, telomerase activity, and asymmetric stem‑cell division that segregates damage away from the immortal lineage [[https://www.annualreviews.org/content/journals/10.1146/annurev-genet-022123-040039]]. Telomerase reactivation experiments prove that somatic tissues can regain youthful function when supplied with germline tools [[https://pmc.ncbi.nlm.nih.gov/articles/PMC3057569/]][[https://pmc.ncbi.nlm.nih.gov/articles/PMC3918663/]], yet other germline safeguards remain untested in soma.

AMPK serves as a metabolic relay between soma and germline, mediating signals that establish germline stem‑cell quiescence [[https://doi.org/10.1101/2023.11.15.567172]]. Intriguingly, gut microbes produce IPA, a tryptophan‑derived metabolite that can activate AMPK in various cell types [[https://doi.org/10.1101/2024.08.30.610454]][[https://doi.org/10.1038/s41467-020-15119-w]][[https://www.science.org/doi/10.1126/sciadv.adw8410]]. We hypothesize that IPA‑driven

Hypothesis

Baseline levels of fecal short‑chain fatty acid (SCFA)‑producing bacteria and host polymorphisms in the kynurenine pathway enzymes (IDO1, TDO2) predict whether a specific prebiotic (e.g., galacto‑oligosaccharides) will augment the clinical effect of SSRIs in major depressive disorder.

Rationale

• Prebiotics increase fecal serotonin and shift the kynurenine‑to‑tryptophan ratio, but trial results show only a nonsignificant trend (SMD: -0.28) [1].
• Heterogeneity in gut microbial composition leads to variable SCFA production; individuals with low baseline SCFA‑producer abundance may not generate sufficient metabolites to influence central tryptophan metabolism [2].
• Host genetic variation in IDO1/TDO2 alters flux through the kynurenine pathway, affecting neuroactive metabolites that modulate mood [3].
• Combining metagenomic profiling of SCFA‑producer taxa with genotyping of kynurenine enzymes creates a predictive biomarker panel that identifies participants likely to benefit from prebiotic‑SSRI synergy.

Prediction

In a randomized, double‑blind, placebo‑controlled trial, participants stratified as 'high predicted responders' (high baseline SCFA‑producer abundance + favorable kynurenine genotype) receiving galacto‑oligosaccharides plus an SSRI will show a significantly greater reduction in MADRS scores than low‑predicted responders receiving the same prebiotic‑SSRI combo or placebo‑SSRI.

Falsifiability

If the interaction between stratification status and treatment does not produce a significant difference in depressive symptom change (